Lyell Immunopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held virtually on June 14, 2024. Lyell Immunopharma, Inc. is a Delaware corporation with its principal executive offices in South San Francisco, California. The company's common stock trades on The Nasdaq Global Select Market under the symbol "LYEL."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders representing 77.98% of outstanding shares (198,815,570 shares) attended the meeting, constituting a quorum. Three proposals were voted upon:
- Proposal 1: Election of Class III Directors
- Elizabeth Nabel, M.D.: Elected with 147,841,830 votes for (74.4% of total votes cast).
- Lynn Seely, M.D.: Elected with 150,085,827 votes for (75.5% of total votes cast).
- Proposal 2: Ratification of Independent Auditor
- Ernst & Young LLP was ratified with 198,604,866 votes for (99.9% of total votes cast).
- Proposal 3: Advisory Vote on Executive Compensation
- Approved with 108,778,036 votes for (54.7% of total votes cast). Notably, 46,997,736 votes were cast against the proposal.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the voting results.
Key Facts for Investor Verification
- Verify the significant "Against" vote (approx. 23.6%) on the executive compensation advisory proposal, which may indicate shareholder sentiment regarding pay practices.
- Confirm the tenure of the newly elected directors, Elizabeth Nabel and Lynn Seely, who will serve until the 2027 annual meeting.
- Review the definitive proxy statement (Schedule 14A filed April 22, 2024) for detailed context on the compensation proposal and director qualifications.